deltatrials
Completed PHASE2 NCT00000461

Harvard Atherosclerosis Reversibility Project (HARP)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia
Interventions cholestyramine fatty acids, omega-3 gemfibrozil niacin pravastatin
Updated 5 times since 2017 Last updated: Mar 15, 2016 Started: Dec 31, 1986 Completion: Nov 30, 1992

Listed as NCT00000461, this PHASE2 trial focuses on Cardiovascular Diseases and Coronary Disease and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 5 times since 1986, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 1986

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.